当前位置: X-MOL 学术Toxicol. In Vitro › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A comparative in vitro toxicity assessment of electronic vaping product e-liquids and aerosols with tobacco cigarette smoke.
Toxicology in Vitro ( IF 2.6 ) Pub Date : 2020-04-27 , DOI: 10.1016/j.tiv.2020.104866
R Wieczorek 1 , G Phillips 2 , L Czekala 2 , E Trelles Sticken 1 , G O'Connell 2 , L Simms 2 , K Rudd 2 , M Stevenson 2 , T Walele 2
Affiliation  

The use of electronic vaping products (EVPs) continues to increase worldwide among adult smokers in parallel with accumulating information on their potential toxicity and relative safety compared to tobacco smoke. At this time, in vitro assessments of many widely available EVPs are limited. In this study, an in vitro battery of established assays was used to examine the cytotoxic (Neutral red uptake), genotoxic (In vitro micronucleus) and mutagenic (Bacterial reverse mutation) responses of two commercial EVPs (blu GO™ disposable and blu PLUS+™ rechargeable) when compared to smoke from a reference cigarette (3R4F). In total, 12 commercial products were tested as e-liquids and as aerosols. In addition, two experimental base liquids containing 1.2% and 2.4% nicotine were also assessed to determine the effect of flavour and nicotine on all three assays. In the bacterial reverse mutation (Ames) and in vitro micronucleus (IVM) assays, exposures to e-liquids and EVP aerosols, with and without nicotine and in a range of flavourings, showed no mutagenic or genotoxic effects compared to tobacco smoke. The neutral red uptake (NRU) assay showed significantly reduced cytotoxicity (P < .05) for whole undiluted EVP aerosols compared to tobacco smoke, which by contrast was markedly cytotoxic even when diluted. The reduced in vitro toxicological responses of the EVPs add to the increasing body of scientific weight-of-evidence supporting the role of high-quality EVPs as a harm reduction tool for adult smokers.

中文翻译:


电子烟产品电子液体和气溶胶与烟草烟雾的体外毒性比较评估。



全球范围内,电子烟产品 (EVP) 的使用在成年吸烟者中持续增加,同时有关其潜在毒性和相对于烟草烟雾的相对安全性的信息也在不断积累。目前,对许多广泛使用的 EVP 的体外评估还很有限。在本研究中,使用一组已建立的体外测定法来检查两种商业 EVP(blu GO™ 一次性和 blu PLUS+™)的细胞毒性(中性红摄取)、基因毒性(体外微核)和诱变(细菌回复突变)反应。可充电)与参考香烟(3R4F)的烟雾进行比较。总共有 12 种商业产品作为电子液体和气雾剂进行了测试。此外,还评估了含有 1.2% 和 2.4% 尼古丁的两种实验基础液体,以确定风味和尼古丁对所有三种测定的影响。在细菌回复突变 (Ames) 和体外微核 (IVM) 测定中,与烟草烟雾相比,暴露于含有或不含尼古丁以及一系列调味剂的电子液体和 EVP 气雾剂中,没有显示出致突变或基因毒性作用。中性红吸收 (NRU) 测定显示,与烟草烟雾相比,整个未稀释的 EVP 气溶胶的细胞毒性显着降低 (P < .05),相比之下,即使稀释后,烟草烟雾也具有明显的细胞毒性。 EVP 体外毒理学反应的降低增加了越来越多的科学证据支持高质量 EVP 作为成年吸烟者减害工具的作用。
更新日期:2020-04-27
down
wechat
bug